Just like there are good and bad macrophages..., there are good and bad NK cells!! This has profound therapeutic implications, far beyond oncology! Thanks to CD for highlighting both papers and the superb and efficient editorial work! Thanks to our collaborators (especially Zihai Li) and funders!
Delighted to have contributed to this piece in Cell: Mapping Intratumor Heterogeneity Across Layers, part of the special issue celebrating the Hallmarks of Cancer. Thanks to @yardenasamuels.bsky.social for her leadership on this one.
authors.elsevier.com/sd/article/S...
Big shout-out to Hadrien De Blander and huge thanks to all involved!
π New preprint! Meet ORIGAMI: Mapping cancer cell state heterogeneity and plasticity, predicting and steering therapy-induced trajectories to rationalize genotype-agnostic combination strategies with only two physical metrics (cell surface area and volume)
www.researchsquare.com/article/rs-8...
Cancer cell plasticity is viewed as a driver of therapy resistance. Here, we propose the concept of βField-Orientedβ Therapyβleveraging plasticity rather than merely enduring it. To learn more, read: aacrjournals.org/cancerdiscov...
To learn more, join my talk at the annual AACR meeting in San Diego (April 18, Discovery Science Plenary: The Next Frontier in Minimal Residual Disease).
Special thanks to Hadrien DeBlander!
@aacrjournals.bsky.social
@vib-ccb.bsky.social
www.linkedin.com/posts/vib_hi...
This concept is based on our recent work (www.researchsquare.com/article/rs-8...).
Unmissable for those working on melanoma and beyond.
Registration for Cancer Cell Plasticity closes on Monday 03 November!
Join us online to explore the fundamental mechanisms that control cancer cell plasticity at multiple biological levels:
eacr.org/conference/c...
Intra-tumour heterogeneity (ITH) and cellular plasticity contribute to therapy resistance. Single-cell transcriptomics is the gold standard for assessing ITH, but this approach remains costly and slow...
